Abiraterone Acetate: Precision CYP17 Inhibitor for Prostate
2026-05-22
Abiraterone acetate, a potent CYP17 inhibitor, unlocks new frontiers in advanced prostate cancer research by enabling robust 3D spheroid and in vivo workflows. This guide translates bench evidence into stepwise protocols, troubleshooting tactics, and comparative insights for translational scientists.
LC–MS/MS Mapping of GS-441524 Prodrug Conversion Pathways
2026-05-21
This study introduces a novel GS-441524 prodrug (NGP-1) designed to improve oral bioavailability and antiviral potential against SARS-CoV-2. Using a newly established LC–MS/MS method, the authors detail the conversion pathways and pharmacokinetics of NGP-1, providing an advanced framework for anti-SARS-CoV-2 nucleoside analog research.
Pam3CSK4: Optimizing TLR1/2 Agonist Workflows for Immune Mod
2026-05-21
Pam3CSK4 enables precise, reproducible TLR1/2-driven immune cell activation for advanced modeling of inflammatory and neuro-immune responses. This guide translates recent neuro-immune discoveries into actionable assay workflows, troubleshooting strategies, and cross-disciplinary insights for researchers seeking robust immune modulation.
3-Methyladenine in Autophagy Research: Protocols & Innovatio
2026-05-20
3-Methyladenine (3-MA) unlocks precision autophagy modulation by dual targeting class I and III PI3K, supporting advanced cancer and cell migration research. This guide delivers actionable protocols, troubleshooting insights, and highlights from the latest cuproptosis research to elevate your experimental design.
Bardoxolone Methyl: Redox Modulation for Translational Impac
2026-05-20
This thought-leadership article explores Bardoxolone methyl (CDDO methyl ester) as a keystone tool for redox pathway modulation in disease models. Blending mechanistic insight with strategic guidance, it addresses the biological rationale for targeting Nrf2 and NF-kB pathways, validates emerging combinatorial strategies in cancer and kidney disease, and offers practical protocol parameters. Integrating recent breakthroughs in thioredoxin system biology and leveraging evidence from preclinical and translational studies, the article positions Bardoxolone methyl as an advanced asset for researchers seeking to bridge bench discoveries to clinical innovation.
DMG-PEG2000-NH2: Scientific Foundations and Next-Gen Drug De
2026-05-19
Explore how DMG-PEG2000-NH2, an advanced NH2-PEG derivative, redefines lipid nanoparticle and liposomal drug delivery. This in-depth analysis unveils mechanistic insights, protocol parameters, and the broader scientific context for biomedical research.
DiR (DiIC 18 (7)) Powers Next-Gen EV Tracking & MPS Evasion
2026-05-19
Explore how DiR (DiIC 18 (7)), a deep-red near-infrared membrane probe from APExBIO, unlocks advanced extracellular vesicle (EV) tracking and enables innovative 'Engage & Evasion' strategies for overcoming mononuclear phagocyte system (MPS) clearance. This thought-leadership article synthesizes mechanistic insights, peer-reviewed evidence, and strategic workflow guidance to chart a new course for translational researchers in regenerative medicine.
Epigenetic Mcl-1 Targeting Synergizes with BCL-XL Inhibition
2026-05-18
This study uncovers a synergistic lethality in glioblastoma models when epigenetic suppression of Mcl-1 is combined with BCL-XL/BCL-2 inhibition, offering a new strategy to overcome apoptotic resistance. Mechanistically, the research reveals how disrupting Mcl-1 super-enhancer regions sensitizes tumor cells to BH3-mimetics, establishing a robust framework for combination therapies.
Dual-Action Kinase Inhibitors Enhance p38α MAPK Dephosphoryl
2026-05-18
This study reveals that certain kinase inhibitors not only block p38α MAP kinase activity but also promote its dephosphorylation by stabilizing an activation loop conformation accessible to phosphatases. These findings provide a mechanistic framework for designing dual-action inhibitors with improved specificity and suggest new strategies for targeting kinase signaling in disease contexts.
Nicotine, nAChRs, and Chronic Kidney Disease Progression
2026-05-17
This review elucidates how nicotine signaling accelerates chronic kidney disease (CKD) progression by activating non-neuronal nicotinic acetylcholine receptors in renal tissues. The findings highlight mechanistic links between smoking and CKD, offering a foundation for targeted molecular research into anti-fibrotic and anti-angiogenic strategies.
GRE Combination Inhibits Melanogenesis via CREB/MITF Modulat
2026-05-16
This study systematically evaluates a combination of glabridin, resveratrol, and ellagic acid (GRE) for its anti-melanogenic, antioxidant, and anti-inflammatory activities in vitro. By demonstrating that GRE suppresses melanin synthesis through downregulation of the CREB/MITF pathway, the work advances mechanistic understanding and provides a foundation for future pigmentation regulation research.
Probenecid (4-(dipropylsulfamoyl)benzoic acid): Mechanisms &
2026-05-15
Probenecid is a well-characterized inhibitor of organic anion transporters, multidrug resistance-associated proteins (MRPs), and pannexin-1 channels. It is widely applied in research to reverse multidrug resistance in leukemia and to provide neuroprotection in cerebral ischemia/reperfusion models. This article details its mechanism, experimental utility, and key limitations.
Host-Directed GSK3 Inhibition for Tuberculosis Control: Insi
2026-05-15
This article examines recent evidence demonstrating that targeting host glycogen synthase kinase 3 (GSK3) effectively restricts Mycobacterium tuberculosis (Mtb) growth within macrophages. The findings suggest a promising host-directed therapy pathway that may complement or provide alternatives to traditional antimicrobial strategies, with implications for multi-drug resistant tuberculosis treatment.
Multi-Omics Networks Reveal ARID1A-Driven Resistance in Mela
2026-05-14
This study integrates multi-omics data to dissect resistance mechanisms to BRAF/MAPK inhibitors in melanoma, focusing on the role of ARID1A loss. The findings identify key signaling nodes and immune evasion pathways that inform future strategies to overcome therapy resistance in metastatic melanoma.
DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023): E
2026-05-14
This article explores how the DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) addresses key experimental challenges in cell viability and cytotoxicity assays. Leveraging 1,164 validated, cell-permeable compounds targeting critical cancer pathways, SKU L1023 empowers reliable screening, reproducibility, and pathway deconvolution for modern cancer research.
462 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page